Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators. Tempero MA, et al. Among authors: frassineti gl. J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521097 Free PMC article. Clinical Trial.
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, Morano F, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, Pietrantonio F; GONO Foundation Investigators. Lonardi S, et al. Among authors: frassineti gl. J Clin Oncol. 2023 Dec 1;41(34):5263-5273. doi: 10.1200/JCO.23.00506. Epub 2023 Aug 3. J Clin Oncol. 2023. PMID: 37535876 Clinical Trial.
Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value.
Vannini I, Rossi T, Melloni M, Valgiusti M, Urbini M, Passardi A, Bartolini G, Gallio C, Azzali I, Bandini S, Ancarani V, Montanaro L, Frassineti GL, Fabbri F, Rapposelli IG. Vannini I, et al. Among authors: frassineti gl. Mol Ther Methods Clin Dev. 2023 May 11;29:473-482. doi: 10.1016/j.omtm.2023.05.009. eCollection 2023 Jun 8. Mol Ther Methods Clin Dev. 2023. PMID: 37273899 Free PMC article.
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F. Yau T, et al. Among authors: frassineti gl. J Clin Oncol. 2023 Mar 20;41(9):1747-1757. doi: 10.1200/JCO.22.00972. Epub 2022 Dec 13. J Clin Oncol. 2023. PMID: 36512738 Free PMC article. Clinical Trial.
Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A, Azzali I, Bittoni A, Marisi G, Rebuzzi F, Molinari C, Bartolini G, Matteucci L, Sullo FG, Debonis SA, Gallio C, Monti M, Valgiusti M, Muratore M, Rapposelli IG, Ulivi P, Frassineti GL. Passardi A, et al. Among authors: frassineti gl. Ther Adv Med Oncol. 2023 Dec 11;15:17588359231212184. doi: 10.1177/17588359231212184. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38107830 Free PMC article.
Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin.
Fausti V, De Vita A, Vanni S, Ghini V, Gurrieri L, Riva N, Casadei R, Maraldi M, Ercolani G, Cavaliere D, Pacilio CA, Pieri F, Foca F, Bongiovanni A, Ranallo N, Calpona S, Frassineti GL, Ibrahim T, Mercatali L. Fausti V, et al. Among authors: frassineti gl. Cancers (Basel). 2023 Feb 8;15(4):1080. doi: 10.3390/cancers15041080. Cancers (Basel). 2023. PMID: 36831421 Free PMC article.
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs.
Reggidori N, Bucci L, Santi V, Stefanini B, Lani L, Rampoldi D, Ghittoni G, Farinati F, Masotto A, Stefanini B, Mega A, Biasini E, Foschi FG, Svegliati-Baroni G, Sangiovanni A, Campani C, Raimondo G, Vidili G, Gasbarrini A, Celsa C, Di Marco M, Giannini EG, Sacco R, Brunetto MR, Azzaroli F, Magalotti D, Morisco F, Rapaccini GL, Nardone G, Vitale A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Reggidori N, et al. JHEP Rep. 2023 May 5;5(8):100784. doi: 10.1016/j.jhepr.2023.100784. eCollection 2023 Aug. JHEP Rep. 2023. PMID: 37520672 Free PMC article.
Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
Marisi G, Azzali I, Passardi A, Rebuzzi F, Bartolini G, Urbini M, Canale M, Molinari C, Matteucci L, Sullo FG, Debonis SA, Gallio C, Gallo G, Frassineti GL, Ulivi P. Marisi G, et al. Among authors: frassineti gl. Sci Rep. 2023 Aug 9;13(1):12921. doi: 10.1038/s41598-023-40220-7. Sci Rep. 2023. PMID: 37558720 Free PMC article. Clinical Trial.
160 results